Introduction
============

Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with an extremely poor prognosis. Among radically operated patients in high-volume centers, five-year survival rates are as low as 4%--34%, with a median survival ranging between 17 and 27 months.[@b1-cmar-11-599]

Subsequent second primary malignant neoplasm (SMN) is a term used to describe a new primary cancer that occurs in a patient who has been diagnosed and treated for cancer in the past, months or years after the original primary cancer. SMNs are a major cause of mortality and serious morbidity among cancer survivors who have been successfully cured of their first cancer. Their etiologies are multiple and may relate to the role of primary cancer treatment (mainly radiotherapy and chemotherapy), unhealthy lifestyle behaviors, germline and somatic mutations, aging, and most likely a combination of any of these factors.[@b2-cmar-11-599],[@b3-cmar-11-599] Because of the unfavorable prognosis, very few long-term PDAC survivors will develop SMN.[@b2-cmar-11-599],[@b3-cmar-11-599] Consequently, there are very few reports about SMNs in PDAC survivors and their prognosis, and there is no information on the genetic background of these patients.[@b2-cmar-11-599]--[@b9-cmar-11-599]

The aim of the present study was to identify and describe SMNs in long-term PDAC survivors with regard to their potential genetic background. This is the first study describing the genetic background of long-term PDAC survivors with SMNs.

Patients and methods
====================

Patients
--------

This retrospective study involved 118 Caucasian patients with PDAC, who had undergone a curative-intent surgery between 2006 and 2011 at the University Hospital, Olomouc, Czech Republic.

The inclusion criteria for further SMN analysis included a curative-intent surgical treatment, histologic diagnosis of PDAC independently confirmed by two experienced pathologists, at least a five-year survival period after surgery, and postresection follow-up comprising biochemical tumor marker monitoring (CA 19-9, CEA, and CA 125) every 3 months and imaging (computed tomography \[CT\] or positron emission tomography \[PET\]/CT) scans performed every 6--12 months or in the case of CA 19-9 elevation.

The clinical data, including age, gender, date of diagnosis, pTNM stage,[@b10-cmar-11-599] the histologic type and grade of the tumor, lymphatic, vascular, and perineural invasion, the therapy administered and follow-up, were obtained from medical records. The main clinical characteristics of the whole group are summarized in [Table 1](#t1-cmar-11-599){ref-type="table"}. The retrospective study was approved by the Institutional Review Board of the University Hospital in Olomouc, and all living patients gave their informed written consent to participation in the study and the genetic analysis. The study was conducted in accordance with the Declaration of Helsinki.

The principal objective of this study was the identification of SMNs in this cohort of patients. The criteria used for the definition of SMN were derived from Waren and Gates, including a histologic confirmation of the second primary malignancy, anatomical separations of both tumors or recurrence exclusion, and a second tumor diagnosis \>6 months after the diagnosis of the first tumor.[@b2-cmar-11-599] The SMNs in the studied cohort were diagnosed by physical examination, endoscopy, and/or diagnostic imaging (CT/PET-CT) and were histologically verified.

Next-generation sequencing analysis
-----------------------------------

Blood was collected during diagnostic procedures using tubes with K~3~EDTA anticoagulant, and DNA was isolated from lymphocytes using the phenol/chloroform extraction method described by Sugimura.[@b11-cmar-11-599]

A custom-designed CZECANCA panel (SeqCap EZ choice; Nimblegen/Roche) for the germline-targeted next-generation sequencing (NGS) analysis of cancer-predisposition and candidate genes was used as described previously.[@b12-cmar-11-599] In brief, the panel targets 219 selected genes with a known predisposition to hereditary cancer syndromes (including breast, ovarian, colorectal, pancreatic, gastric, endometrial, kidney, prostate, and skin cancers) and other genes that code for proteins involved in the DNA repair and/or DNA damage response with uncertain clinical relevance. A sequencing library was prepared using the KAPA HTP Library Preparation kit according to the manufacturer's instructions (KAPA Biosystems, Roche) and sequenced on the MiSeq instrument with MiSeq reagent Kit v3 (Illumina).

Bioinformatics analysis
-----------------------

The NGS data were processed according to the in-house bioinformatics pipeline as described recently.[@b12-cmar-11-599] In brief, SAM files were generated from FASTQ files using Novoalign v2.08.03 and transformed into BAM files using Picard tools v1.129. The VCF files prepared by GATK were annotated by ANNOVAR.[@b13-cmar-11-599] Medium-size indel identification was based on the method of soft-clipped bases using Pindel software, and copy number variation (CNV) analysis was performed using CNV kit. During variant filtration, we excluded low-quality variants (sequence quality \<30) and common variants with allelic frequencies \>0.01 in ESP6500 and 1,000 genomes databases, respectively. We also excluded variants present \>2× in a national database of genotypes that included 507 noncancer controls (data not shown). Nonsense, frameshift, and consensus dinucleotide splice site variants (±1/2) in known predisposition genes were classified as pathogenic or likely pathogenic. Missense variants, silent variants, in-frame indels, and other intronic variants were considered only when reaching a CADD score \>2 and gerp \>0 and classified according to the ClinVar and/or VarSome database. Prioritized variants were further analyzed by three prediction tools (SIFT, PolyPhen-2, and Mutation Analyzer). Variants predicted to be damaging by at least two programs were considered potentially deleterious.

Results
=======

Patients and treatment
----------------------

Twenty-two patients (19.1%) with histopathologically verified PDAC survived for \>5 years since the primary PDAC diagnosis (long-term survivors) and matched the inclusion criteria for this retrospective study. The median follow-up was 6.2 years (range 5--11 years). Long-term PDAC survivors were further screened for the development of SMNs.

Overall, six patients (5.1% of all radically resected PDAC patients) developed SMNs. The SMN rate among long-term survivors was 27% (N=6/22). The mean age of the long-term PDAC survivors at the time of PDAC diagnosis was 61.7±7.8 years (range 44--75 years). The subgroup of patients with SMNs consisted of five males and only one female; the mean age was 66.7±7.4 years (range 51--75 years) at the time of PDAC diagnosis. None of these patients received neoadjuvant chemotherapy. One patient was treated with chemotherapy based on 5-fluorouracil (300 mg/m^2^/day) concomitant to radiotherapy (50.4 Gy in 5.5 weeks) in the adjuvant setting, and the other five patients were treated with six 4-week cycles of gemcitabine (1000 mg/m^2^ at days 1, 8, and 22). Overall, of the long-term PDAC survivors in the present cohort, around 40% of patients who received gemcitabine postoperatively developed subsequent malignant neoplasms. The clinical and pathologic data of the patients with SMN are summarized in [Table 2](#t2-cmar-11-599){ref-type="table"}.

Timing and patterns of subsequent secondary malignant neoplasms
---------------------------------------------------------------

The median time to SMN was 52.5 months (range 8.8--87.1 months; [Table 2](#t2-cmar-11-599){ref-type="table"}). The SMNs observed included two cases of rectal cancer, and one case each of prostate cancer, malignant melanoma, breast cancer, and urinary bladder cancer. Four of these patients underwent a curative surgery for the SMN. The patient with urinary bladder cancer underwent a radical cystectomy 63 months after PDAC resection. The patient with malignant melanoma underwent a radical excision 45.4 months after PDAC resection, and the patient with breast cancer underwent mastectomy 8.8 months after PDAC resection. All these patients are still alive with no recurrence of primary or secondary malignancy (6.3--8.9 years following the primary surgery of PDAC). One patient with rectal cancer died of postoperative complications from rectal surgery 64 months after the PDAC surgery. A second patient with rectal cancer died of cardiovascular comorbidities 62 months after the PDAC surgery without a specific therapy.

Prostate cancer with bone metastases was diagnosed in one patient 87.1 months after the primary PDAC resection and the patient was treated with hormonal therapy.

In summary, none of these patients died as a result of the PDAC.

Genetic analysis
----------------

A targeted NGS analysis covering 219 PDAC and other cancer susceptibility genes ([Table 3](#t3-cmar-11-599){ref-type="table"}) was performed in 20 patients both with and without SMNs (DNA samples from the two deceased patients with rectal cancer were not available).

Deleterious germline mutations were identified in 4 out of 20 NGS-analyzed long-term survivors (20%; [Table 4](#t4-cmar-11-599){ref-type="table"}). One patient harbored two deleterious mutations (in *MLH1* and *ATM*). Of the four sequenced long-term survivors who developed SMN, one female patient who developed breast cancer 1 year after primary PDAC diagnosis with no family cancer history carried a deleterious missense mutation in *CHEK2* (c.349A\>G, p.Arg117Gly). Two out of 3 carriers of a pathogenic mutation in 16 long-term PDAC survivors without SMN had a positive family cancer history. A patient with *RAD51D* splice-site mutation c.345+2T\> G had a mother with gastric cancer and a patient with two mutations (nonsense variant in *MLH1*: c.390C\>G and frame-shift variant in *ATM*: c.3849delA) had a father with a colorectal cancer and a father's mother with brain tumor. The remaining patient with the *CHEK2* c.1100delC mutation had no personal or family cancer history.

Subsequently, we identified several alterations with unknown impact on protein function. Fourteen variants in ten patients were predicted to be damaging by at least three prediction programs ([Table 5](#t5-cmar-11-599){ref-type="table"}).

Discussion
==========

This report demonstrates a relatively high incidence of SMNs in five-year survivors of PDAC. The incidence of SMNs is generally 2%--10% and the prevalence is 6.6%--9%, accounting for about 16% of overall cancer incidence.[@b2-cmar-11-599],[@b3-cmar-11-599],[@b5-cmar-11-599] So far, very few publications have reported an analysis of second primary extrapancreatic malignancies following PDAC, probably because of the poor prognosis of these patients.[@b2-cmar-11-599],[@b6-cmar-11-599]--[@b9-cmar-11-599] A large population-based study calculated the incidence of SMNs diagnosed after the diagnosis of PDAC to be lower when compared to other cancers (around 1.3%).[@b8-cmar-11-599],[@b14-cmar-11-599] The latest report of the Czech National Cancer Registry shows a primary PDAC incidence of about 84% and a second primary PDAC (PDAC as the second primary tumor) incidence of about 16%. The incidence of synchronous PDAC and other malignancies is 5% of total PDAC patient incidence and the incidence of SMNs following PDAC is \<1% of the total.[@b15-cmar-11-599] These rates were confirmed by the study reported by Hackert et al.[@b16-cmar-11-599]

The unexpectedly high number of SMNs (5%) in the present cohort of resected PDAC patients may be primarily explained by the comprehensive follow-up focusing not only on PDAC recurrence, but also on SMNs. Moreover, among long-term PDAC survivors, we identified SMNs in 27% of patients, indicating that the apparently limited number of SMNs in PDAC reported so far may be largely due to the poor prognosis. Previously published reports on long-term PDAC survivors show prevalences of SMNs ranging between 0% and 20%.[@b6-cmar-11-599],[@b7-cmar-11-599] Nevertheless, this retrospective analysis may indicate that the development of SMNs in PDAC survivors may be more frequent than has been acknowledged in previous reports.

Improved medical options including anticancer therapy and treatment individualization lead to the prolongation of survival. This is evident in survivors of various primary cancers, including PDAC survivors.[@b17-cmar-11-599] The same trend has also been confirmed in the Czech population.[@b18-cmar-11-599] A higher age at the time of the primary PDAC diagnosis was the only remarkable difference between five-year survivors with SMNs and those without SMNs. The incidence of cancer increases with age, and, consequently, older survivors have a higher risk of SMNs than younger survivors. All patients with a manifestation of SMN received adjuvant chemotherapy consisting of antimetabolites gemcitabine or 5-fluorouracil. Although patients who undergo chemotherapy are generally considered to be at a higher risk of SMN, an increased risk of SMNs after the use of these antimetabolites has not been reported to date.

Therefore, it seems that a higher age at the time of the PDAC diagnosis and a long-term survival after a surgical and chemotherapy treatment may be regarded as risk factors for SMNs, and that such patients should be diagnostically followed.

The NGS analysis revealed five clearly pathogenic variants in four patients from the long-term PDAC survivors subgroup (25%). This frequency was higher than for the other group of 96 unselected PDAC patients,[@b19-cmar-11-599] which was 13.5% identified with a panel of 22 genes, but we are aware of the small number of patients analyzed in our study. A recent study by Yurgelun et al[@b20-cmar-11-599] identified 28 carriers of germline pathogenic or likely pathogenic mutations in double-strand DNA damage repair genes in 289 patients (9.7%) with resected PDAC. Interestingly, the authors demonstrated that the germline mutations carriers had superior overall survival (HR 0.54; *P* = 0.05). This indicates that mutations in cancer-predisposing genes increase the risk of prognostically beneficial PDAC; therefore, it might be expected that an increased proportion of mutation carriers should also be found among the long-term PDAC survivors. Unfortunately, the genetic aberrations discovered do not currently seem to be of any clinical relevance with regard to potential therapeutic options.

Considering the small number of long-term survivors, the frequency of pathogenic variants in the group of patients who developed SMNs (25%) and in the group who did not (19%) was comparable. These results suggest that SMN development may be due to a combined effect of variants with low penetrance or may be caused by a combination of genetic and/or nongenetic risk factors. On the other hand, the presence of germline mutations did not dramatically influence risk and prognosis of SMN.

The patient with PDAC at 70 years old and subsequent breast cancer at 71 was identified to harbor a pathogenic missense *CHEK2* variant (c.349A\>G, p.Arg117Gly). Numerous studies and meta-analyses have shown that mutations in the *CHEK2* gene are clearly associated with increased breast cancer risk and also with the development of other solid or hematologic tumors.[@b21-cmar-11-599] We failed to find a significant association of *CHEK2* germline variants with unselected PDAC cases in our previous study; however, only selected portions of *CHEK2* coding sequence were analyzed.[@b22-cmar-11-599] Since then, germline *CHEK2* mutations have been identified in several studies in patients with PDAC;[@b19-cmar-11-599],[@b20-cmar-11-599],[@b23-cmar-11-599],[@b24-cmar-11-599] however, a consensual evaluation of *CHEK2* germline variants in PDAC remains to be established.

In a subgroup of 16 long-term PDAC survivors without SMN development, we identified 2 PDAC patients with pathogenic variants in cancer predisposition genes and a positive family history. *MLH1* is a Lynch syndrome predisposition gene[@b25-cmar-11-599] and can explain the colorectal cancer in the patient's father. *RAD51D* is an ovarian cancer predisposition gene,[@b26-cmar-11-599] but was never associated with gastric cancer. These data indicate that germline mutations in cancer predisposition genes are associated with a wider range of phenotypes than previously suggested.

The evaluation of potentially pathogenic missense germ-line variants in candidate genes requires further analysis in larger groups of PDAC patients, as well as functional studies, because in silico predictions are suitable for variant prioritization for such analyses, but are not devoted to final variant classification.

The present study, therefore, poses new questions regarding the role of genetic alterations in the development of PDAC and subsequent SMNs in patients, and regarding the modification of the clinical course of the disease. The variants identified in the present study must be verified by further investigations, also in regard to the functional impact. However, this is the first study of genetic alterations in SMNs in PDAC patients and the largest epidemiologic retrospective analysis of SMNs after PDAC treatment in Central Europe.

Conclusion
==========

In our cohort, 27% of five-year PDAC survivors went on to develop SMNs. An intensive follow-up can identify the second primary neoplasms early, at a curable stage. SMN risk factors include a longer survival and a higher age at the time of PDAC diagnosis. Genetic analysis has confirmed the role of pathogenic mutations in pancreatic and other cancers' predisposition genes in long-term surviving PDAC patients; nevertheless, the frequency did not differ in the subgroups with and without SMN development. If the performance status of these patients allows and a second primary tumor has a favorable prognosis, subsequent surgery should be performed.
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###### 

Baseline patient characteristics (entire cohort)

  Parameters                    Number of patients[\*](#tfn1-cmar-11-599){ref-type="table-fn"}   \%
  ----------------------------- ---------------------------------------------------------------- ----
  **Sex**                                                                                        
  Male                          75                                                               64
  Female                        43                                                               36
  **TNM stage**                                                                                  
  I                             20                                                               17
  IIA                           34                                                               29
  IIB                           54                                                               46
  III                           2                                                                2
  IV                            8                                                                7
  **Histologic grade**                                                                           
  G1 + G2 (well to moderate)    62                                                               52
  G3 (poor)                     51                                                               44
  Not available                 5                                                                4
  **Lymphovascular invasion**                                                                    
  pL0                           74                                                               63
  pL1                           38                                                               32
  Not available                 6                                                                5
  **Perineural invasion**                                                                        
  pP0                           35                                                               30
  pP1                           77                                                               65
  Not available                 6                                                                5
  **Angioinvasion**                                                                              
  pA0                           91                                                               77
  pA1                           21                                                               18
  Not assessed                  6                                                                5
  **Adjuvant therapy**                                                                           
  Yes                           79                                                               68
  No                            37                                                               31
  Unknown                       2                                                                2

**Note:**

118 patients in total.

###### 

Clinical data of patients with SMN

  Sex      Age   pT   pN   Grade   Perineural invasion   Angioinvasion   Lymphovascular invasion   Adjuvant treatment   Family history of PDAC   Family history of other cancers   DFS   SMN                      TTS   Treatment of SMN   TTT   OS    Status
  -------- ----- ---- ---- ------- --------------------- --------------- ------------------------- -------------------- ------------------------ --------------------------------- ----- ------------------------ ----- ------------------ ----- ----- --------
  Male     68    3    0    3       Yes                   No              No                        GEM                  No                       No                                64    Rectal cancer            60    Surgery            60    64    Died
  Male     69    2    1    3       No                    No              No                        GEM                  No                       No                                105   Urinary bladder cancer   17    Surgery            63    105   Alive
  Male     67    3    1    3       No                    No              No                        GEM                  Yes                      No                                14    Malignant melanoma       45    Surgery            45    104   Alive
  Male     51    3    0    2       Yes                   No              Yes                       GEM                  No                       No                                92    Prostate cancer          87    Hormonal therapy   87    92    Alive
  Male     75    2    0    1       No                    No              No                        R/5FU                No                       No                                62    Rectal cancer            61    None               NA    62    Died
  Female   70    3    0    2       No                    No              Yes                       GEM                  No                       No                                73    Breast cancer            9     Surgery            9     73    Alive

**Abbreviations:** pT, pathologic tumor size; pN, pathologic lymph node metastasis; DFS, disease-free survival (months); NA, not applicable; SMN, subsequent secondary malignant neoplasm; TTS, time to diagnosis of SMN (months); TTT, time to therapy of SMN (months); OS, overall survival (months); GEM, gemcitabine (six cycles); R/5 FU, concomitant chemoradiotherapy with 5-fluorouracil; PDAC, pancreatic ductal adenocarcinoma.

###### 

List of genes analyzed by targeted next-generation sequencing

  Abbreviation   Gene name (alternative denominations)
  -------------- --------------------------------------------------------------------------------------------------------
  *AIP*          Aryl hydrocarbon receptor interacting protein
  *ALK*          Anaplastic lymphoma kinase
  *APC*          Adenomatous polyposis coli
  *APEX1*        APEX nuclease (multifunctional DNA repair enzyme) 1
  *ATM*          Ataxia telangiectasia mutated
  *ATMIN*        ATM interactor
  *ATR*          Ataxia telangiectasia and Rad3 related
  *ATRIP*        ATR interacting protein
  *AURKA*        Aurora kinase A
  *AXIN1*        Axin 1
  *BABAM1*       BRISC and BRCA1 A complex member 1
  *BAP1*         BRCA1-associated protein-1 (ubiquitin carboxy-terminal hydrolase)
  *BARD1*        BRCA1-associated RING domain 1
  *BLM*          Bloom syndrome, RecQ helicase-like
  *BMPR1A*       Bone morphogenetic protein receptor, type IA
  *BRAP*         BRCA1-associated protein
  *BRCA1*        Breast cancer 1, early onset
  *BRCA2*        Breast cancer 2, early onset
  *BRCC3*        BRCA1/BRCA2-containing complex, subunit 3
  *BRE*          Brain and reproductive organ-expressed (TNFRSF1A modulator)
  *BRIP1*        BRCA1 interacting protein C-terminal helicase 1
  *BUB1B*        Budding uninhibited by benzimidazoles 1 homolog beta (yeast)
  *C11orf30*     Chromosome 11 open reading frame 30 (EMSY)
  *C19orf40*     Chromosome 19 open reading frame 40 (FAAP24)
  *CASP8*        Caspase 8, apoptosis-related cysteine peptidase
  *CCND1*        Cyclin D1
  *CDC73*        Cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (*Saccharomyces cerevisiae*)
  *CDH1*         Cadherin 1, type 1, E-cadherin (epithelial)
  *CDK4*         Cyclin-dependent kinase 4
  *CDKN1B*       Cyclin-dependent kinase inhibitor 1B (p27, Kip1)
  *CDKN1C*       Cyclin-dependent kinase inhibitor 1C (p57, Kip2)
  *CDKN2A*       Cyclin-dependent kinase inhibitor 2A
  *CEBPA*        CCAAT/enhancer binding protein (C/EBP), alpha
  *CEP57*        Centrosomal protein 57 kDa
  *CLSPN*        Claspin
  *CSNK1D*       Casein kinase 1, delta
  *CSNK1E*       Casein kinase 1, epsilon
  *CWF19L2*      CWF19-like 2, cell cycle control (*Schizosaccharomyces pombe*)
  *CYLD*         Cylindromatosis (turban tumor syndrome)
  *DCLRE1C*      DNA cross-link repair 1C
  *DDB2*         Damage-specific DNA binding protein 2, 48 kDa
  *DHFR*         Dihydrofolate reductase
  *DICER1*       Dicer 1, ribonuclease type III
  *DMC1*         DMC1 dosage suppressor of mck1 homolog, meiosis-specific homologous recombination (yeast)
  *DNAJC21*      DnaJ (Hsp40) homolog, subfamily C, member 21
  *DPYD*         Dihydropyrimidine dehydrogenase
  *EGFR*         Epidermal growth factor receptor
  *EPCAM*        Epithelial cell adhesion molecule
  *EPHX1*        Epoxide hydrolase 1, microsomal (xenobiotic)
  *ERCC1*        Excision repair cross-complementing rodent repair deficiency, complementation group 1
  *ERCC2*        Excision repair cross-complementing rodent repair deficiency, complementation group 2
  *ERCC3*        Excision repair cross-complementing rodent repair deficiency, complementation group 3
  *ERCC4*        Excision repair cross-complementing rodent repair deficiency, complementation group 4
  *ERCC5*        Excision repair cross-complementing rodent repair deficiency, complementation group 5
  *ERCC6*        Excision repair cross-complementing rodent repair deficiency, complementation group 6
  *ESR1*         Estrogen receptor 1
  ESR2           Estrogen receptor 2 (ER beta)
  EXO1           Exonuclease 1
  EXT1           Exostosin 1
  EXT2           Exostosin 2
  EYA2           Eyes absent homolog 2 (Drosophila)
  EZH2           Enhancer of zeste homolog 2 (Drosophila)
  FAM175A        Family with sequence similarity 175, member A
  FAM175B        Family with sequence similarity 175, member B
  FAN1           FANCD2/FANCI-associated nuclease 1
  FANCA          Fanconi anemia, complementation group A
  FANCB          Fanconi anemia, complementation group B
  FANCC          Fanconi anemia, complementation group C
  FANCD2         Fanconi anemia, complementation group D2
  FANCE          Fanconi anemia, complementation group E
  FANCF          Fanconi anemia, complementation group F
  FANCG          Fanconi anemia, complementation group G
  FANCI          Fanconi anemia, complementation group I
  FANCL          Fanconi anemia, complementation group L
  FANCM          Fanconi anemia, complementation group M
  FBXW7          F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase
  FH             Fumarate hydratase
  FLCN           Folliculin
  GADD45A        Growth arrest and DNA-damage-inducible, alpha
  GATA2          GATA binding protein 2
  GPC3           Glypican 3
  GRB7           Growth factor receptor-bound protein 7
  HELQ           Helicase, POLQ-like
  HNF1A          HNF1 homeobox A
  HOXB13         Homeobox B13
  HRAS           v-Ha-ras Harvey rat sarcoma viral oncogene homolog
  HUS1           HUS1 checkpoint homolog (S. pombe)
  CHEK1          Checkpoint kinase 1
  CHEK2          Checkpoint kinase 2
  KAT5           K(lysine) acetyltransferase 5
  KCNJ5          Potassium inwardly rectifying channel, subfamily J, member 5
  KIT            V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
  LIG1           Ligase I, DNA, ATP-dependent
  LIG3           Ligase III, DNA, ATP-dependent
  LIG4           Ligase IV, DNA, ATP-dependent
  LMO1           LIM domain only 1 (rhombotin 1)
  LRIG1          Leucine-rich repeats and immunoglobulin-like domains 1
  MAX            MYC-associated factor X
  MCPH1          Microcephalin 1
  MDC1           Mediator of DNA-damage checkpoint 1
  MDM2           Mdm2, p53 E3 ubiquitin protein ligase homolog (mouse)
  MDM4           Mdm4 p53 binding protein homolog (mouse)
  MEN1           Multiple endocrine neoplasia I
  MET            Met proto-oncogene (hepatocyte growth factor receptor)
  MGMT           O-6-methylguanine-DNA methyltransferase
  MLH1           mutL homolog 1, colon cancer, nonpolyposis type 2 (Escherichia coli)
  MLH3           mutL homolog 3 (E. coli)
  MMP8           Matrix metallopeptidase 8 (neutrophil collagenase)
  MPL            Myeloproliferative leukemia virus oncogene
  MRE11A         MRE11 meiotic recombination 11 homolog A (S. cerevisiae)
  MSH2           mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)
  MSH3           mutS homolog 3 (E. coli)
  MSH5           mutS homolog 5 (E. coli)
  MSH6           mutS homolog 6 (E. coli)
  MSR1           Macrophage scavenger receptor 1
  MUS81          MUS81 endonuclease homolog (S. cerevisiae)
  MUTYH          mutY homolog (E. coli)
  NAT1           N-acetyltransferase 1 (arylamine N-acetyltransferase)
  NBN            Nibrin
  NCAM1          Neural cell adhesion molecule 1
  NELFB          Cofactor of BRCA1
  NF1            Neurofibromin 1
  NF2            Neurofibromin 2 (merlin)
  NFKBIZ         Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta
  NHEJ1          Nonhomologous end-joining factor 1
  NSD1           Nuclear receptor binding SET domain protein 1
  OGG1           8-oxoguanine DNA glycosylase
  PALB2          Partner and localizer of BRCA2
  PARP1          Poly (ADP-ribose) polymerase 1
  PCNA           Proliferating cell nuclear antigen
  PHB            Prohibitin
  PHOX2B         Paired-like homeobox 2b
  PIK3CG         Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma
  PLA2G2A        Phospholipase A2, group IIA (platelets, synovial fluid)
  PMS1           PMS1 postmeiotic segregation increased 1 (S. cerevisiae)
  POLB           Polymerase (DNA directed), beta
  POLD1          Polymerase (DNA directed), delta 1, catalytic subunit
  POLE           Polymerase (DNA directed), epsilon, catalytic subunit
  PPM1D          Protein phosphatase, Mg2+/Mn2+ dependent, 1D
  PREX2          Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2
  PRF1           Perforin 1 (pore forming protein)
  PRKAR1A        Protein kinase, cAMP-dependent, regulatory, type I, alpha
  PRKDC          Protein kinase, DNA-activated, catalytic polypeptide
  PTEN           Phosphatase and tensin homolog
  PTCH1          Patched 1
  PTTG2          Pituitary tumor-transforming 2
  RAD1           RAD1 homolog (S. pombe)
  RAD17          RAD17 homolog (S. pombe)
  RAD18          RAD18 homolog (S. cerevisiae)
  RAD23B         RAD23 homolog B (S. cerevisiae)
  RAD50          RAD50 homolog (S. cerevisiae)
  RAD51          RAD51 homolog (S. cerevisiae)
  RAD51AP1       RAD51 associated protein 1
  RAD51B         RAD51 homolog B (S. cerevisiae)
  RAD51C         RAD51 homolog C (S. cerevisiae)
  RAD51D         RAD51 homolog D (S. cerevisiae)
  RAD52          RAD52 homolog (S. cerevisiae)
  RAD54B         RAD54 homolog B (S. cerevisiae)
  RAD54L         RAD54-like (S. cerevisiae)
  RAD9A          RAD9 homolog A (S. pombe)
  RB1            Retinoblastoma 1
  RBBP8          Retinoblastoma binding protein 8
  RECQL          RecQ protein-like (DNA helicase Q1-like)
  RECQL4         RecQ protein-like 4
  RECQL5         RecQ protein-like 5
  RET            Ret proto-oncogene
  RFC1           Replication factor C (activator 1) 1, 145 kDa
  RFC2           Replication factor C (activator 1) 2, 40 kDa
  RFC4           Replication factor C (activator 1) 4, 37 kDa
  RHBDF2         Rhomboid 5 homolog 2 (Drosophila)
  RNF146         Ring finger protein 146
  RNF168         Ring finger protein 168, E3 ubiquitin protein ligase
  RNF8           Ring finger protein 8, E3 ubiquitin protein ligase
  RPA1           Replication protein A1, 70 kDa
  RUNX1          Runt-related transcription factor 1
  SDHAF2         Succinate dehydrogenase complex assembly factor 2
  SDHB           Succinate dehydrogenase complex, subunit B, iron sulfur (Ip)
  SETBP1         SET binding protein 1
  SETX           Senataxin
  SHPRH          SNF2 histone linker PHD RING helicase, E3 ubiquitin protein ligase
  SLX4           SLX4 structure-specific endonuclease subunit homolog (S. cerevisiae)
  SMAD4          SMAD family member 4
  SMARCA4        SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4
  SMARCB1        SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1
  SMARCE1        SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily e, member 1
  STK11          Serine/threonine kinase 11
  SUFU           Suppressor of fused homolog (Drosophila)
  TCL1A          T-cell leukemia/lymphoma 1A
  TELO2          TEL2, telomere maintenance 2, homolog (S. cerevisiae)
  TERF2          Telomeric repeat binding factor 2
  TERT           Telomerase reverse transcriptase
  TLR2           Toll-like receptor 2
  TLR4           Toll-like receptor 4
  TMEM127        Transmembrane protein 127
  TOPBP1         Topoisomerase (DNA) II binding protein 1
  TP53           Tumor protein p53
  TP53BP1        Tumor protein p53 binding protein 1
  TSC1           Tuberous sclerosis 1
  TSC2           Tuberous sclerosis 2
  TSHR           Thyroid stimulating hormone receptor
  UBE2A          Ubiquitin-conjugating enzyme E2A
  UBE2B          Ubiquitin-conjugating enzyme E2B
  UBE2I          Ubiquitin-conjugating enzyme E2I
  UBE2V2         Ubiquitin-conjugating enzyme E2 variant 2
  UBE4B          Ubiquitination factor E4B
  UIMC1          Ubiquitin interaction motif containing 1
  VHL            Von Hippel--Lindau tumor suppressor, E3 ubiquitin protein ligase
  WRN            Werner syndrome, RecQ helicase-like
  WT1            Wilms tumor 1
  XPA            Xeroderma pigmentosum, complementation group A
  XPC            Xeroderma pigmentosum, complementation group C
  XRCC1          X-ray repair complementing defective repair in Chinese hamster cells 1
  XRCC2          X-ray repair complementing defective repair in Chinese hamster cells 2
  XRCC3          X-ray repair complementing defective repair in Chinese hamster cells 3
  XRCC4          X-ray repair complementing defective repair in Chinese hamster cells 4
  XRCC5          X-ray repair complementing defective repair in Chinese hamster cells 5
  XRCC6          X-ray repair complementing defective repair in Chinese hamster cells 6
  ZNF350         Zinc finger protein 350
  ZNF365         Zinc finger protein 365

###### 

Table of identified variants classified as likely pathogenic/pathogenic according to the ClinVar database

  Patient           Gene       Nucleotide    Protein       ClinVar classification   Sex/age primary   Personal history (age at diagnosis)   Family history
  ----------------- ---------- ------------- ------------- ------------------------ ----------------- ------------------------------------- -------------------------------------------
  **With SMN**                                                                                                                              
  OL0138            *CHEK2*    c.349A\>G     p.Arg117Gly   Class 4--5               Female/70         Breast (71)                           0
  **Without SMN**                                                                                                                           
  OL0130            *RAD51D*   c.345+2T\>G   --            Class 4                  Male/62           0                                     Mother -- gastric
  OL0132            *MLH1*     c.390C\>G     p.Tyr130Ter   Class 5                  Female/52         0                                     Father -- colon, father's mother -- brain
                    *ATM*      c.3849delA    p.Leu1283fs   Class 5                                                                          
  PCI77             *CHEK2*    c.1100delC    p.Thr367fs    Class 5                  Male/55           0                                     0

**Note:** All variants are heterozygous.

**Abbreviation:** SMN, subsequent malignant neoplasm after pancreatic ductal adenocarcinoma (PDAC).

###### 

List of identified variants of unknown significance

  Patient                                                   Gene               Nucleotide        Protein            rs number     EXaC MAF   ClinVar/VarSome classification   SIFT        PP2         MA          Damag. acc. to ≥2 software
  --------------------------------------------------------- ------------------ ----------------- ------------------ ------------- ---------- -------------------------------- ----------- ----------- ----------- ----------------------------
  **With SMN**                                                                                                                                                                                                    
  OL0134                                                    ***BLM***          **c.11**T\>C      **p.Val4Ala**      rs144706057   0.0017     1--3/3                           **0**       0.132       **2.14**    Y
  OL0135                                                    ***PTCH1***        **c.2597**G\>A    **p.Gly866Glu**    NA            NA         3/3                              0.08        **0.999**   **2.31**    Y
  *ATM*                                                     c.3208G\>A         p.Val1070Ile      NA                 NA            3/3        0.35                             0.026       **2.135**   N           
  OL0136                                                    ***PLA2G2A***      **c.185**G\>A     **p.Arg62His**     NA            8.34E-05   NA/3                             **0.02**    0.888       **3.005**   Y
  ***LRIG1***                                               **c.2195**C\>T     **p.Pro732Leu**   rs61746346         0.0022        NA/3       **0**                            **0.991**   **1.975**   Y           
  *RECQL5*                                                  c.1801G\>A         p.Val601Met       NA                 NA            NA/3       0.3                              0.04        **1.905**   N           
  OL0138                                                    *PREX2*            c.C1672G          p.Pro558Ala        rs199541834   0.0001     NA/3                             0.15        0.145       0.46        N
  *PARP1*                                                   c.C659T            p.Ala220Val       rs139232092        0.0006        NA/3       0.15                             0.003       1.155       N           
  **Without SMN**                                                                                                                                                                                                 
  OL0041                                                    *BUB1B*            c.1042G\>A        p.Ala348Thr        NA            8.24E-06   NA/3                             0.33        0.85        **2.175**   N
  *MRE11A*                                                  c.C1475A           p.Ala492Asp       rs61749249         0.0034        1--3/3     0.43                             0.754       1.735       N           
  OL0130                                                    ***XRCC1***        **c.632**A\>G     **p.Tyr211Cys**    NA            1.74E-05   NA/3                             0.15        **0.998**   **2.175**   Y
  OL0131                                                    *0*                                                                                                                                                   
  OL0132                                                    ***GRB7***         **c.1439**T\>C    **p.Val480Ala**    rs143372931   0.0004     NA/3                             **0**       0.848       **3.07**    Y
  *RAD9A*                                                   c.215G\>A          p.Arg72His        rs377299831        1.65E-05      NA/3       0.58                             0.019       1.2         N           
  OL0133                                                    ***EXT2***         **c.1859**C\>T    **p.Thr620Met**    rs138495222   0.0006     2--3/3                           **0.02**    **0.999**   **2.24**    Y
  ***MLH3****[a](#tfn6-cmar-11-599){ref-type="table-fn"}*   **c.**3281-1G\>C   --                NA                 NA            NA/3       --                               --          --          --          
  OL0137                                                    *PREX2*            c.2167A\>G        p.Asn723Asp        NA            1.65E-05   NA/3                             **0.03**    0.614       1.63        N
  ***HELQ***                                                **c.1418**G\>A     **p.Arg473His**   NA                 2.48E-05      NA/3       **0**                            **1**       **4.545**   Y           
  *RFC4*                                                    c.908C\>T          p.Ala303Val       rs144238574        9.07E-05      NA/3       0.44                             0.027       1.235       N           
  OL0139                                                    *RHBDF2*           c.940G\>A         p.Ala314Thr        rs140433374   0.0008     NA/3                             0.33        **0.952**   1.78        N
  *MDM4*                                                    c.1162C\>G         p.Pro388Ala       rs61754765         0.0006        NA/3       0.92                             **0.997**   1.1         N           
  OL0140                                                    ***FANCM***        **c.3407**T\>C    **p.Leu1136Ser**   NA            1.65E-05   NA/3                             **0.01**    **0.963**   **1.905**   Y
  ***POLE***                                                **c.1601**T\>C     **p.Leu534Pro**   NA                 NA            NA/3       **0**                            **0.991**   **3.565**   Y           
  OL0141                                                    *0*                                                                                                                                                   
  OL0142                                                    ***RAD54L***       **c.1817**G\>A    **p.Arg606Gln**    rs374574941   2.47E-05   NA/3                             **0**       **1**       **4.735**   Y
  ***POLD1***                                               **c.2116**C\>G     **p.Pro706Ala**   NA                 NA            3/3        **0.01**                         0.733       **2.41**    Y           
  OL0144                                                    *CWF19L2*          c.2240A\>C        p.Lys747Ther       NA            NA         NA/3                             0.08        0.697       **1.915**   N
  ***SETX***                                                **c.967**A\>G      **p.Ser323Gly**   NA                 1.65E-05      NA/3       **0**                            **0.994**   0.975       Y           
  OL0157                                                    *TP53BP1*          c.2226A\>T        p.Glu742Asp        rs150423877   0.0004     NA/3                             0.48        **0.987**   0.46        N
  PCI77                                                     *0*                                                                                                                                                   
  PCI15                                                     *PTCH1*            c.3376G\>A        p.Val1126Ile       rs147025073   0.0005     3/3                              0.26        **0.927**   1.77        N
                                                            *NCAM1*            c.1481C\>A        p.Thr494Asn        NA            NA         NA/3                             **0.01**    0.347       NA          N
  PCI39                                                     *0*                                                                                                                                                   
  PCO11                                                     *BRCA1*            c.3929C\>A        p.Thr1310Lys       rs80357257    8.24E-06   1--3/3                           **0.01**    0.787       1.895       N
  *AURKA*                                                   c.1028G\>A         p.Arg343Gln       rs200181472        0.0002        NA/3       **0.04**                         0.027       0.71        N           
  *EXO1*                                                    c.820G\>A          p.Gly274Arg       rs149397534        0.0021        NA/3       0.16                             **0.999**   1.295       N           

**Notes:** The variants predicted to be damaging by at least two out of three prediction tools employed are represented in bold.

The splice-site variant was analyzed by splicing prediction software spidex with a score −25.6359, suggesting that it is the damaging variant.

**Abbreviation:** NA, not applicable.

[^1]: These authors contributed equally to this work
